YaleCME
CONTINUING MEDICAL EDUCATION

APRIL SEMINAR NOTICE

Presented by

Yale School of Medicine's, Department of Therapeutic Radiology

"Monofunctional Alkylating Agents Sensitize MGMT-Deficient Tumor Cells to ATR Inhibitors"

Christopher Jackson, Postgraduate Fellow
Therapeutic Radiology Department
Yale School of Medicine

Date: Thursday, April 18, 2019, 9:00AM
Location: Smilow LL505

Course Director/Host: Henry S. Park, MD, MPH
There is no corporate support for this activity
This course will fulfill the licensure requirement set forth by the State of Connecticut

ACCREDITATION
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE
Attending Physicians; Housestaff/Fellows; Medical Students; Nurses; PA's; Other

NEEDS ASSESSMENT
O6-Methylguanine-Methyltransferase (MGMT) is a DNA repair enzyme that is deficient in numerous types of tumors relative to normal tissue. These MGMT-deficient tumor cells are sensitive to the alkylating agent temozolomide. However, use of temozolomide is restricted to only a few cancers. This study was designed to determine whether DNA repair inhibitors could increase the efficacy of the drug. Source: 10.1158/0008-5472.CAN-16-2983

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to
1. What is MGMT and what cancers are characterized by MGMT deficiency?
2. What is the mechanism of action of temozolomide and other alkylating agents?
3. What DNA repair deficiency makes cells resistant to the combination of temozolomide and ATR inhibitors?

DESIGNATION STATEMENT
The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES
Christopher Jackson, Medical Student –None; Henry S. Park, MD, MPH – None

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.